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HIGHLIGHTS
The effects of apelin on pulmonary hemodynamics in patients with PAH are unknown.
Systemic infusion caused a significant reduction in pulmonary vascular resistance and increase in cardiac output without a change in heart rate or systemic vascular resistance.
This effect was most prominent in the subgroup of patients receiving concomitant PDE5 inhibition.
Apelin agonism is a novel potential therapeutic target for PAH.
ISSN 2452-302X https://doi.org/10.1016/j.jacbts.2018.01.013 Apelin is an endogenous peptide that was first discovered in 1998. It binds to a previously orphaned G-protein-coupled receptor, now termed the apelin receptor (3). Apelin receptors are present on endothelial cells, vascular smooth muscle cells, and cardiomyocytes (4). In preclinical models, apelin signaling exerts major effects on both vascular tone and cardiac contractility leading to vasorelaxation (5), falls in arterial blood pressure and systemic venous tone (6) (7) (8) (9) , and potent inotropism (10) with increased cardiac contractility.
We have previously conducted clinical studies looking at the effects of apelin in healthy volunteers and patients with heart failure (11, 12) . We showed apelin to be a direct coronary and peripheral vasodilator, to increase myocardial contractility, and to reduce peak and end-diastolic left ventricular pressure (13) . We also demonstrated that these inotropic actions were maintained during prolonged 6-h infusions (12) .
Apelin infusion improves pulmonary vascular hemodynamics in 2 animal models of PAH (14, 15) , and this may translate into benefit for patients with PAH by reducing PVR and increasing cardiac output (CO). Given these preclinical and clinical data, we sought to determine the short-term pulmonary hemodynamic effects of intravenous apelin infusion in patients with PAH.
METHODS
This was a double-blind randomized crossover study of the short-term hemodynamic effects of apelin in 
A P R I L 2 0 1 8 : 1 7 6 -8 6 All subjects fasted for at least 4 h before the procedure and avoided alcohol or caffeine for 24 h before the study. Patients delayed taking routine medication on the morning of the right heart catheterization until completion of the study protocol.
DRUGS. The effects of apelin agonism were determined using synthetic-grade (Pyr 1 )apelin-13 (Clinalfa, Laufelfingen, Switzerland) (11, 13) . This was administered after dissolution in 0.9% physiological saline (Baxter, Deerfield, Illinois) under aseptic conditions on the study day.
PLASMA APELIN CONCENTRATIONS. In a group of patients (n ¼ 8), plasma apelin concentrations were measured to ensure that the infusion had raised apelin levels. Plasma (Pyr 1 )apelin-13 concentration was deter- PROTOCOL. Each study was conducted in a quiet and temperature-controlled investigation suite with subjects in the supine position. Heart rate, electrocardiogram, pulse oximetry, and systemic arterial blood pressure were monitored continuously throughout.
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An 8-F sheath was placed in the right internal jugular vein using ultrasound imaging, or brachial vein using standard aseptic techniques. A Swan-Ganz catheter (7-F, 2 lumen, thermodilution pressure-measuring tipped catheter; Edwards Lifesciences, Irvine, California) was passed into the pulmonary artery.
In a randomized, double-blinded, crossover design, each participant received three 5-min intravenous infusions of ascending doses of (Pyr 1 )
apelin-13 at 10, 30, and 100 nmol/min (11, 13) software, GraphPad Software, San Diego, California).
Statistical significance was taken as 2-sided p < 0.05.
RESULTS
Study participants were predominantly female and middle-aged ( Table 1 ). All studies were well tolerated with no serious adverse events or electrocardiographic changes during apelin administration. Nineteen subjects were included in the analysis (2 subjects were excluded because of protocol deviations).
Before apelin infusion, there were no detectable basal plasma apelin concentrations in patients with PAH.
Following infusion with (Pyr 1 )apelin-13, there was a marked increase in plasma apelin concentrations (peak concentration, 10,681 AE 4,184 pmol/l). The individual data for each study participant are included in Table 2 . Values are mean AE SEM or n/N (%).
BMI ¼ body mass index; CO ¼ cardiac output; CTD PH ¼ connective tissue disease pulmonary hypertension; ERA ¼ endothelin receptor antagonist; Hb ¼ hemoglobin; IPAH ¼ idiopathic pulmonary arterial hypertension; MAP ¼ mean arterial pressure; mPAP ¼ mean pulmonary artery pressure; NYHA ¼ New York Heart Association; PAWP ¼ pulmonary arterial wedge pressure; PDE5i ¼ phosphodiesterase inhibitor; PVR ¼ pulmonary vascular resistance; RAP ¼ right atrial pressure; SV ¼ stroke volume; SVR ¼ systemic vascular resistance. HR ¼ heart rate; other abbreviations as in Table 1 .
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Brash et al. EXERCISE. During exercise (n ¼ 9), there were no differences in any of the hemodynamic variables except PVR ( Figure 2 ) and heart rate. The increase in PVR was attenuated during (Pyr 1 )apelin-13 infusion (p < 0.05), and this was associated with an increase in heart rate (p < 0.01). This study was designed as an invasive study because this is the most accurate method of determining changes in hemodynamic variables. The study design was a within-subject, blinded, randomized, crossover study in order to enhance statistical power and robust comparisons of effects. We designed the study to measure both resting and exercise hemodynamics because patients with PAH are more symptomatic during activity, and we hoped to demonstrate that apelin has therapeutic benefit both at rest and during exercise. Interestingly, we were able to demonstrate improvements in pulmonary hemodynamics at rest, but surprisingly, improvements were not greater when the subjects exercised. This may be because of the large changes in hemodynamics caused by exercise, which may have obscured the more subtle changes observed at rest. It may be that longer-term apelin agonism could lead to an improvement in exercise pulmonary hemodynamics, and this may be worth examining in future studies.
The apelin system may have major relevance for patients with PAH. Dysfunction of bone morphogenetic protein (BMP) signaling is an important pathway in the pathogenesis of PAH (23), and it appears to influence apelin production as a potential mediator of Brash et al.
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Brash et al. Furthermore, apelin can directly suppress vascular smooth muscle cell proliferation in response to growth factors, and is proapoptotic (15) . Importantly, long-term apelin administration was associated with positive inotropism without any evidence of myocardial hypertrophy in murine models of PAH (6) .
In previous studies, we provided the first evidence that apelin has vasoactive actions in humans. We showed that apelin causes vasodilatation in vivo in the human forearm circulation of healthy volunteers through a predominantly NO-dependent mechanisms, and that this effect is preserved in patients with heart failure (11, 13) . Furthermore, we showed that apelin is a direct coronary vasodilator and increases myocardial contractility in humans. It caused a reduction in both peak and end-diastolic left ventricular pressures (13) . Here, we show that similar effects are also seen in pulmonary hemodynamics in patents with PAH.
It is also noted that there is not a dose-effect relationship, with a plateauing of PVR and CO at the higher infusion rates (Figure 1 ). This is consistent with results seen in our previous studies (13) and is why we had chosen to reduce the doses of our infusion rates during this study. This may reflect the doses we have chosen or an "all or nothing" effect.
We included patients who were taking PDE5 inhibitors in this study. It is known that in ex vivo myography studies, inhibition of NO attenuated apelin-induced vasorelaxation in human mesenteric arteries (5) . As we demonstrated in our previous clinical study (11) , the effects of apelin are partially attenuated with an "NO clamp" (concomitant balanced infusion of a NO donor and a NO synthase inhibitor) suggesting that apelin causes arterial vasodilation via a NO-dependent manner. PDE5 inhibitors also act on the NO pathway by preventing degradation of cGMP. We felt it was important to include this group for recruitment in our study to determine whether there was any synergistic vasodilatory effect when combining 2 drugs that act on the NO-cGMP pathway. Interestingly, on post hoc analysis, the group of patients established on PDE5 inhibitors had more marked improvements in PVR, CO, and SV, whereas the group who were not on treatment with PDE5 inhibitors (includes treatment naive and those on treatments other than PDE5 inhibitors)
showed no demonstrable effect. This study was not powered to investigate this effect directly, but it would be important for future studies to explore this interaction further. It should also be noted that the group on PDE5 inhibitors had more severe baseline hemodynamic abnormalities, and demonstrated a reduction in SVR with apelin infusion consistent with our previous observations in patients with heart failure (11,13). It was not possible to assess the symptomatic impact of these short-term changes in the patients as they were supine on the catheterization table.
Currently, there is a great deal of interest in upfront combination treatment for PAH to determine whether this has long-term beneficial effects in patients with PAH by the establishment of early control and preservation of RV function. These benefits need to be balanced with the potential for drug-drug interactions and potential adverse effects.
We did not demonstrate any adverse effects in our study, but this would need to be explored further in long-term studies.
This study examined the short-term effects of apelin administration, and longer studies are needed to determine long-term hemodynamic benefits, as well as potential long-term adverse effects.
We have previously determined the effect of prolonged systemic infusion of apelin in man. During 6-h infusions of apelin in healthy volunteers and patients with heart failure, apelin was well tolerated and its inotropic actions were maintained, with a sustained increase in cardiac index and left ventricular ejection fraction (12) . Furthermore, we previously monitored pulmonary artery blood flow during the first hour of apelin infusion using echocardiography and found this to be increased with apelin infusion versus saline placebo. This suggests that apelin will have sustained benefits on pulmonary vascular hemodynamics.
Apelin has also been shown in preclinical studies to target pulmonary vascular remodeling (15), so not only does it have beneficial hemodynamic effects in the human pulmonary vasculature, but it may also prevent the pulmonary vasculature remodeling seen in PAH. However, this has yet to be established. apeacock@udcf.gla.ac.uk.
